throbber

`
`
`
`Baxley
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`Trademark Trial and Appeal Board
`P.O. Box 1451
`Alexandria, VA 22313-1451
`General Contact Number: 571-272-8500
`General Email: TTABInfo@uspto.gov
`
`February 19, 2019
`
`Opposition No. 91245889
`
`Celator Pharmaceuticals, Inc.
`
`v.
`
`
`Andrew P. Baxley, Interlocutory Attorney:
`
`Vytalyx Inc. dba Vytalyx
`
`After the Board, in a January 29, 2019 order (5 TTABVUE), rejected the parties’
`
`stipulation (filed January 21, 2019, 4 TTABVUE) to amend involved application
`
`Serial No. 87719755, Applicant, on February 13, 2019, the parties filed a renewed
`
`stipulation to amend that application.
`
`By the renewed proposed amendment, the parties agree to amend the
`
`identification of goods in International Class 5 from
`
`Compounded pharmaceuticals, namely, sterile injectables, non-sterile
`solutions, suspensions, ointments, creams, powders, capsules, tablets
`and troches for use in the areas of, Weight management, Erectile
`dysfunction treatment, Male hormone replacement treatment, Female
`hormone replacement treatment, Bio-identical hormone replacement,
`Adrenal dysfunction treatment, Thyroid dysfunction treatment, Pain
`management, Palliative care, Sports medicine, Amino acid replacement
`therapy, Mineral replacement therapy, Vitamin replacement therapy,
`Anti-aging therapy, Dermatology, Fertility, Growth Hormone therapy;
`and Anticonvulsant agents, Antihypertensive agents, Antidiabetic
`agents, Non-steroidal anti-inflammatory agents, Anesthetic agents,
`Vasoactive agents, Lipotropic agents, Chelating agents, Psychoactive
`agents; Compounded personalized pharmaceuticals, namely, sterile
`
`
`
`

`

`Opposition No. 91245889
`
`
`injectables, non-sterile solutions, suspensions, ointments, creams,
`powders, capsules, tablets and for use in the areas of, Weight
`management, Erectile dysfunction
`treatment, Male hormone
`replacement treatment, Female hormone replacement treatment, Bio-
`identical hormone replacement, Adrenal dysfunction treatment,
`Thyroid dysfunction treatment, Pain management, Palliative care,
`Sports medicine, Amino acid replacement therapy, Mineral replacement
`therapy, Vitamin
`replacement
`therapy, Anti-aging
`therapy,
`Dermatology, Fertility, Growth Hormone therapy; and Anticonvulsant
`agents, Antihypertensive agents, Antidiabetic agents, Non-steroidal
`anti-inflammatory agents, Anesthetic agents, Vasoactive agents,
`Lipotropic agents, Chelating agents, Psychoactive agents; Compounded
`personalized pharmaceuticals, namely, sterile injectables, non-sterile
`solutions, suspensions, ointments, creams, powders, capsules, tablets
`and troches based on medical, genetic, genomic, nutrigenomic,
`pharmacogenomic, microbiomic, metabolomic, proteomic, biochemistry,
`biomarker, health, dietary, nutrition, exercise, physical fitness, lifestyle
`and personal information for use in the areas of, Weight management,
`Erectile dysfunction treatment, Male hormone replacement treatment,
`Female hormone replacement treatment, Bio-identical hormone
`replacement, Adrenal dysfunction treatment, Thyroid dysfunction
`treatment, Pain management, Palliative care, Sports medicine, Amino
`acid replacement therapy, Mineral replacement therapy, Vitamin
`replacement therapy, Anti-aging therapy, Dermatology, Fertility,
`Growth Hormone
`therapy;
`and
`Anticonvulsant
`agents,
`Antihypertensive agents, Antidiabetic agents, Non-steroidal anti-
`inflammatory agents, Anesthetic agents, Vasoactive agents, Lipotropic
`agents, Chelating agents, Psychoactive agents; Genetic marker tests
`comprised of reagents for medical purposes; Medical diagnostic reagents
`and assays for testing of body fluids in the nature of genomic,
`microbiomic, metabolomic, and biochemical tests; Medical diagnostic
`test kits comprised of medical diagnostic reagents and assays used to
`collect test samples for analyzing DNA, blood, hair, saliva and stool
`information for use in DNA, blood, hair, saliva and stool testing of
`humans; Kits comprised of medical diagnostic reagents and assays for
`use in genetic, genomic, microbiomic, metabolomic, and biochemical
`testing; Kits comprised of medical diagnostic reagents and assays for
`use in DNA, blood, hair, saliva and stool testing of humans; Medical
`diagnostic test media in the form of strips, threads, swabs, cartridges,
`and collection tubes for collecting and analyzing genetic, genomic,
`microbiomic, metabolomic, and biochemical data
`
`to (additional wording in bold, deleted wording struck through)
`
`
`
`2
`
`

`

`Opposition No. 91245889
`
`
`pharmaceuticals, namely, Sterile prescription
`Compounded
`injectables, non-sterile prescription
`solutions, prescription
`suspensions, prescription
`ointments, prescription
`creams,
`prescription powders, prescription capsules, prescription tablets
`and prescription troches for use in the areas of Weight management,
`Erectile dysfunction treatment, Male hormone replacement treatment,
`Female hormone replacement treatment, Bio-identical hormone
`replacement, Adrenal dysfunction treatment, Thyroid dysfunction
`treatment, Pain management, Palliative care, Sports medicine, Amino
`acid replacement therapy, Mineral replacement therapy, Vitamin
`replacement therapy, Anti-aging therapy, Dermatology, Fertility,
`Growth Hormone
`therapy;
`and
`Anticonvulsant
`agents,
`Antihypertensive agents, Antidiabetic agents, Non-steroidal anti-
`inflammatory agents, Anesthetic agents, Vasoactive agents, Lipotropic
`agents, Chelating agents, Psychoactive agents; Compounded
`personalized
`pharmaceuticals, namely, Sterile prescription
`injectables, non-sterile prescription
`solutions, prescription
`suspensions, prescription
`ointments, prescription
`creams,
`prescription powders, prescription capsules, prescription tablets
`and troches based on medical, genetic, genomic, nutrigenomic,
`pharmacogenomics, microbiomic, metabolomics, proteomic,
`biochemistry, biomarker, health, dietary, nutrition, exercise,
`physical fitness, lifestyle and personal information for use in the
`areas of, Weight management, Erectile dysfunction treatment, Male
`hormone replacement treatment, Female hormone replacement
`treatment, Bio-identical hormone replacement, Adrenal dysfunction
`treatment, Thyroid dysfunction
`treatment, Pain management,
`Palliative care, Sports medicine, Amino acid replacement therapy,
`Mineral replacement therapy, Vitamin replacement therapy, Anti-aging
`therapy, Dermatology, Fertility, Growth Hormone therapy; and
`Anticonvulsant agents, Antihypertensive agents, Antidiabetic agents,
`Non-steroidal anti-inflammatory agents, Anesthetic agents, Vasoactive
`agents, Lipotropic agents, Chelating agents, Psychoactive agents;
`Compounded personalized pharmaceuticals, namely, sterile injectables,
`non-sterile solutions, suspensions, ointments, creams, powders,
`capsules, tablets and troches based on medical, genetic, genomic,
`nutrigenomic, pharmacogenomic, microbiomic, metabolomic, proteomic,
`biochemistry, biomarker, health, dietary, nutrition, exercise, physical
`fitness, lifestyle and personal information for use in the areas of, Weight
`management, Erectile dysfunction
`treatment, Male hormone
`replacement treatment, Female hormone replacement treatment, Bio-
`identical hormone replacement, Adrenal dysfunction treatment,
`Thyroid dysfunction treatment, Pain management, Palliative care,
`Sports medicine, Amino acid replacement therapy, Mineral replacement
`
`
`
`3
`
`

`

`Opposition No. 91245889
`
`
`therapy,
`therapy, Anti-aging
`replacement
`therapy, Vitamin
`Dermatology, Fertility, Growth Hormone therapy; and Anticonvulsant
`agents, Antihypertensive agents, Antidiabetic agents, Non-steroidal
`anti-inflammatory agents, Anesthetic agents, Vasoactive agents,
`Lipotropic agents, Chelating agents, Psychoactive agents; Genetic
`marker tests comprised of reagents for medical purposes; Medical
`diagnostic reagents and assays for testing of body fluids in the nature of
`genomic, microbiomic, metabolomic, and biochemical tests; Medical
`diagnostic test kits comprised of medical diagnostic reagents and assays
`used to collect test samples for analyzing DNA, blood, hair, saliva and
`stool information for use in DNA, blood, hair, saliva and stool testing of
`humans; Kits comprised of medical diagnostic reagents and assays for
`use in genetic, genomic, microbiomic, metabolomic, and biochemical
`testing; Kits comprised of medical diagnostic reagents and assays for
`use in DNA, blood, hair, saliva and stool testing of humans; Medical
`diagnostic test media in the form of strips, threads, swabs, cartridges,
`and collection tubes for collecting and analyzing genetic, genomic,
`microbiomic, metabolomic, and biochemical data; all of the foregoing,
`excluding pharmaceuticals for the treatment of cancer
`
`A proposed amendment to any application or registration which is the subject of
`
`an inter partes proceeding must also comply with all other applicable rules and
`
`statutory provisions, including Trademark Rules 2.71-2.75. See TBMP §§ 514.01 and
`
`605.03(b). In particular, while an applicant may amend to clarify or limit the
`
`identification, adding to or broadening the scope of the identification is not permitted.
`
`See Trademark Rule 2.71(a); TMEP §§1402.06 et seq., 1402.07. That is, any
`
`amendment to the identification of goods must remain within the scope of the
`
`identification of goods as published for opposition.
`
`The proposed amendment is unacceptable because inasmuch as it identifies goods
`
`are not within the scope of the identification that was published for opposition.1 The
`
`
`1 The revised proposed amendment indicated that the only changes in the identification of
`goods would be deletion of the wording “Compounded pharmaceuticals, namely,” and
`“Compounded personalized pharmaceuticals, namely,” and addition of the wording “all of the
`aforesaid, excluding, pharmaceuticals for the treatment of cancer.” 6 TTABVUE 2. As noted
`
`
`
`4
`
`

`

`Opposition No. 91245889
`
`scope of goods in the identification of goods in International Class 5 that was
`
`published for opposition was defined as “[c]ompounded pharmaceuticals” and
`
`“[c]ompounded personal pharmaceuticals.” The applicable definition of “compound”
`
`is “comprised of two or more substances or parts,” and the applicable definition of
`
`“pharmaceutical” is “[a] drug or medication.” Webster’s II New College Dictionary 231
`
`and 824 (1995). By the proposed amendment, Applicant essentially seeks to redefine
`
`that scope as “prescription” goods. Even if the Board assumes that all such
`
`prescription goods are with the scope of pharmaceuticals and personal
`
`pharmaceuticals, the proposed amended identification is unacceptable because it is
`
`presumed to encompass compounded pharmaceuticals and personal pharmaceuticals,
`
`as well as pharmaceuticals and personal pharmaceuticals that are composed of a
`
`single substance. Cf. In re Elbaum, 211 USPQ 639, 640 (TTAB 1981) (where goods
`
`are broadly identified and there are no limitations as to their nature, type, channels
`
`of trade or classes of purchasers, the Board must presume that the scope of the
`
`identified goods encompasses all goods of the nature and type described, that those
`
`goods move in all channels of trade that would be normal for such goods, and that the
`
`goods would be purchased by all potential customers). Thus, any amendment must
`
`stay within the broader classification of “[c]ompounded pharmaceuticals” and
`
`
`supra, the proposed amendment included far greater additional wording than “all of the
`aforesaid, excluding, pharmaceuticals for the treatment of cancer.” The parties are reminded
`that their redlining of proposed amendments should accurately reflect additions and
`deletions from the identifications of goods and/or services at issue.
`
`
`
`
`5
`
`

`

`Opposition No. 91245889
`
`“[c]ompounded personal pharmaceuticals,” as Applicant defined its goods prior to
`
`publication of its mark for opposition.
`
`In view of this determination, the motion to amend is denied without prejudice.
`
`The present identification of goods in International Class 5, that is, the identification
`
`prior to the filing of the motion to amend, remains operative for purposes of future
`
`amendment. See Trademark Rule 2.71(a); TMEP §1402.07(d).
`
`However, inasmuch as the filing of the proposed amendment indicates to the
`
`Board that the parties are making efforts to settle this matter, proceedings are
`
`suspended, and the parties are allowed until thirty days from the date of this
`
`order to file a revised motion to amend, failing which the Board will resume
`
`proceedings and reset dates, and the opposition will go forward on the present
`
`application.
`
`
`
`
`
`6
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket